| |
Total MCI
|
sMCI
|
cMCI
|
|---|
|
Urine
| | | |
|
Participants
|
209
|
167
|
42
|
|
Male/female
|
95/114
|
80/87
|
15/27
|
|
Mean age (SD)
|
76.33 (6.03)
|
76.17 (5.60)
|
76.91 (7.38)
|
|
MMSE
|
26.86 (2.75)
|
26.93 (2.94)
|
26.55 (1.76)
|
|
CDR
|
0.49 (0.08)
|
0.48 (0.09)
|
0.51 (0.08)
|
|
Reported SSRI medication
|
16
|
12
|
4
|
|
Serum
| | | |
|
Participants
|
165
|
90
|
75
|
|
Male/female
|
71/94
|
42/48
|
29/46
|
|
Mean age
|
77.50 (6.49)
|
75.98 (5.95)
|
79.32 (6.67)
|
|
MMSE
|
26.73 (2.24)
|
26.81 (2.38)
|
26.63 (2.07)
|
|
CDR
|
0.49 (0.11)
|
0.48 (0.10)
|
0.53 (0.12)
|
|
Reported SSRI medication
|
11
|
8
|
3
|
- Overview of the two MCI subgroups used in the study. All samples in the study were taken at baseline; however, one MCI subgroup remained stable throughout follow-up visits (sMCI), whilst the second converted to a clinical diagnosis of AD at subsequent follow-up visits (cMCI). SSRI selective serotonin reuptake inhibitor, MMSE Mini-Mental State Examination score, CDR Clinical Dementia Rating
